Sun Pharma to launch Takeda gastrointestinal drug in India

Sun Pharma to launch Takeda gastrointestinal drug in India


Drug maker Sun Pharmaceutical Industries has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company, under which Takeda Pharmaceutical Company's gastrointestinal drug Vonoprazan Tablets 10mg, 20mg will be commercialized in India under the brand name Voltapraz.

Discovered and developed by Takeda, Vonoprazan is a new, orally active potassium competitive acid blocker, used to treat reflux esophagitis and other acid peptic disorders. The US FDA approved this drug in November 2023. In India, it is approved to treat adults with reflux esophagitis and other acid peptic disorders.

“We are excited to introduce Vonoprazan in India under a non-exclusive patent license from Takeda,” Kirti Ganorkar, CEO of India Trade, said in a release on Friday. Sun Pharma shares closed steady at ₹ 1,464.50 on the BSE.


join us for quick updates

Leave a Reply

Your email address will not be published. Required fields are marked *

Enable Notifications OK No thanks